Prime Medicine, Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
PRME · Price history
Price at last available close
$5.19
+$2.31 (+80.21%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Prime Medicine, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence.
How they make money
Prime Medicine is a biotechnology company that generates revenue primarily through research collaboration agreements with pharmaceutical partners. The company is currently in the development stage and does not have any approved commercial products, meaning it relies on upfront payments, milestone payments, and research funding from these collaborations to support its operations.
Products & services
The company is developing a portfolio of one-time curative genetic therapies using its proprietary Prime Editing platform, which is designed to precisely edit genes to treat various diseases in hematology, immunology, oncology, liver, and lung areas.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Customer concentration
The company's revenue is highly concentrated, as it is derived from a limited number of collaboration agreements with pharmaceutical partners.
Suppliers, materials & equipment
- Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and drug candidates; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Bristol Myers Squibb — A strategic collaboration and license agreement focused on the development of ex vivo T-cell therapies.Source
Competitors
Strengths
Company-specific research
Questions worth answering for PRME
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving PRME's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can PRME fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is PRME's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for PRME to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PRME's current valuation?
Essential Investment Snapshot
Market Cap
$944.6M
P/E Ratio
-2.8
EPS
$-1.10
52-Week High
$6.56
52-Week Low
$2.67
Beta
2.38
Analyst Target
$7.50
Shares Outstanding
148.8M
Total Debt
$112.5M
Dividend
No current dividend
Liquidation Value / Share
$0.27
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for PRME
Detected from reported data — verify before acting.M&A headline · Sep 2, 2026
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on PRME.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary Prime Editing platform technology.
- +Diversified pipeline of therapeutic programs.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on third-party manufacturers and collaborators.
- −Uncertainty of clinical trial success and regulatory approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$5.21
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +55.3%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $4.6M | $3.0M | $0.00 | ···· | ···· | ···· | ···· |
| Cost of Revenue | $7.3M | $7.3M | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Gross Profit | -$3.2M | -$2.7M | $3.0M | $0.00 | ···· | ···· | ···· | ···· |
| Research & Development | $146.2M | $160.6M | $155.3M | $147.9M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $54.4M | $52.3M | $50.2M | $43.4M | ···· | ···· | ···· | ···· |
| Operating Expenses | $193.3M | $205.7M | $205.4M | $204.8M | ···· | ···· | ···· | ···· |
| EBITDA | -$182.4M | -$195.8M | -$189.8M | -$186.6M | ···· | ···· | ···· | ···· |
| Operating Income | -$196.5M | -$208.3M | -$202.5M | -$204.8M | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Income Before Tax | -$187.9M | -$201.1M | -$195.9M | -$198.4M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$279K | ···· | ···· | ···· | ···· |
| Net Income | -$187.9M | -$201.1M | -$195.9M | -$198.1M | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.07 | $-1.35 | $-1.65 | $-2.18 | ···· | ···· | ···· | ···· |
| Basic Shares | 177M | 149M | 119M | 90.97M | ···· | ···· | ···· | ···· |
| Diluted Shares | 177M | 149M | 119M | 90.97M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$1.2M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.24
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-6.1%
Cash Change
-11.8%
Margin Change
+1067.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 3.5%. EPS declined 41.0%. Cash declined 11.8%. Total debt declined 6.1%. Net income margin improved by 1067.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Leading Indicators For The October Breakout Cycle
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Prime Medicine Gets FDA Green Light for Gene Editing Study
Rumor Mill · PRME
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial